Abstract
No public abstract is available from the verified source records.
Herbert Barton Grossman, Frans M.J. Debruyne, Hideyuki Akaza, Yoshio Aso, Susumu Kagawa, Yoshiyuki Kakehi, A.P.M. van der Meijden, Timothy L. Ratliff
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Vinblastine, ifosfamide, and gallium nitrate—an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892)
10.1002/(sici)1097-0142(19970101)79:1<110::aid-cncr16>3.0.co;2-7 · 1997
Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies
10.1016/s0022-5347(01)66765-x · 1995
Oral methotrexate for superficial transitional cell carcinoma of the bladder
10.1016/s0022-5347(17)36281-x · 1995
Prophylactic oral UFT therapy for superficial bladder cancer
10.1002/1097-0142(19930301)71:5<1842::aid-cncr2820710520>3.0.co;2-2 · 1993
Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP study group
10.1159/000475138 · 1995
Antiproliferative effects of tyrosine kinase inhibitors (tyrphostins) on human bladder and renal carcinoma cells
10.1006/jsre.1995.1222 · 1995
Initial report on intravesical administration of n-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder
10.1016/s0090-4295(96)00621-8 · 1997
Immunotargeting of urothelial cell carcinoma with intravesically administered Tc-99m labeled HMFG1 monoclonal antibody
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
openalex
Confidence 95%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1007/bf02789217 · 1994
Radioimmunoimaging diagnosis of human bladder carcinoma
1994
Immunoscintigraphy with iodine-131-labelled monoclonal antibody AUA1 in patients with transitional cell carcinoma of the bladder
10.1007/bf00297203 · 1994
Intravesical administration of indium-111-labelled HMFG2 monoclonal antibody in superficial bladder carcinomas
10.1002/ijc.2910540604 · 1993
Oral bropirimine immunotherapy of carcinoma in situ of the bladder
10.1016/s0090-4295(96)90059-x · 1996
How effective is topical alpha-2b interferon in preventing recurrence of superficial bladder cancer?
10.1111/j.1464-410x.1991.tb15393.x · 1991
Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b
10.1200/jco.1994.12.1.7 · 1994
A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group
10.1111/j.1464-410x.1995.tb00759.x · 1995
Comparison of two doses of interferon-alpha-2b in intravesical prophylaxis of superficial bladder tumors. Portuguese Genito-Urinary Group
10.1159/000475069 · 1995
Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer
10.1016/s0090-4295(96)00375-5 · 1996
Immunotherapeutic alternatives in superficial bladder cancer. Interferon, interleukin-2, and keyhole-limpet hemocyanin
10.1016/s0094-0143(21)00425-0 · 1992
Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2
10.1159/000475070 · 1995
Immunologic reduction of bladder cancer recurrence rate
10.1016/s0022-5347(17)59919-x · 1974
Immunotherapy in bladder cancer with keyhole-limpet hemocyanin
10.1016/s0022-5347(17)42610-3 · 1988
Recurrent superficial transitional cell carcinoma of the bladder
10.1016/s0022-5347(17)39427-2 · 1990
Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer
10.1016/s0022-5347(01)67228-8 · 1995
Is there a role for recombinant tumor necrosis factor alpha in the intravesical treatment of superficial bladder tumors? A phase II study
10.1111/j.1442-2042.1995.tb00433.x · 1995
Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma
10.1111/j.1464-410x.1976.tb02742.x · 1996
Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence
10.1016/s0022-5347(17)52205-3 · 1983
The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial
10.1111/j.1464-410x.1994.tb07547.x · 1994
10.1016/s0022-5347(17)36198-0
10.1016/s0022-5347(17)36198-0 · 1993
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer
10.1016/s0022-5347(01)66226-8 · 1996
Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer
10.1016/s0022-5347(01)66225-6 · 1996
A feasibility study for the non-invasive treatment of superficial bladder tumours with focused ultrasound
10.1046/j.1464-410x.1996.02189.x · 1996
Early clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancer
10.1046/j.1464-410x.1996.09717.x · 1996
Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells
10.1084/jem.177.4.1127 · 1993
Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines
1994
Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer
10.4049/jimmunol.159.1.351 · 1997
Adenovirus-mediated suicide gene therapy for experimental bladder cancer
10.1016/s0090-4295(96)00560-2 · 1997
Intravesical gene therapy
1994
Recombinant adenovirus-mediated gene transfer to genitourinary epithelium in vitro and in vivo
1995
Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy
10.1016/s0022-5347(17)32741-6 · 1994
Megadose vitamins in bladder cancer
10.1016/s0022-5347(17)34863-2 · 1994
10.1002/(sici)1097-4644(1996)25+3.0.co;2-k
10.1002/(sici)1097-4644(1996)25+<197::aid-jcb28>3.0.co;2-k · doi-reference
Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point
10.1093/jnci/86.2.138 · doi-reference
Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland
10.1159/000475068 · doi-reference
13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group
10.1002/jcb.240501328 · doi-reference
10.1159/000475139
10.1159/000475139 · doi-reference